html5-img
1 / 12

Mirrorgroup Animal Health

Mirrorgroup Animal Health. Dutch experiences. Trigger, initiative and chair. Initiative: CVO European trigger: request Executive Board of ETPGAH to deliver input for Action Plan under construction

keegan
Download Presentation

Mirrorgroup Animal Health

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Mirrorgroup Animal Health Dutch experiences

  2. Trigger, initiative and chair • Initiative: CVO • European trigger: request Executive Board of ETPGAH to deliver input for Action Plan under construction • National triggers: - need to strengthen Vet. Research infrastructure- improvement co-operation pharma industry, public research and administration (incl. Registration Authority)- innovation in vaccine development (AI) • Lead: pharma industry (Intervet)

  3. Targets For Europe • Recommendations for Action Plan ETPGAH- gaps and priorities from (shared) Dutch point of view- defining issues of major importance for NLResult: position paper National • Improvement of understanding and co-operation between and among industry, research, administration

  4. Stakeholders • Pharma Industry (Intervet, Pfizer, Fort Dodge, FIDIN) • Research Institutes (Fac. Vet. Med., CIDC, ASG, Animal Health Service) • Administration (CVO, Reg. Authority, 2 Departments of LNV) • Royal Vet. Society • Food and Product Safety Authority

  5. Setting • Temporary Group (max. 3 meetings) • Informal end-afternoon meetings including buffet • Time and opportunity for non-plenary interactions

  6. Topics addressed in 1st meeting • Terms of reference Mirror Group and modus operandi ETPGAHConclusion: recommendations ETPGAH are in general very relevant for the Netherlands. • Clarification of positions and interactions of ETPGAH, SCAR-CWGAH, FP-7 agenda and ERA-net Animal diseases • Registration procedures and thresholds for pharma industry

  7. Main conclusions 1st meeting National level • Research chain (fundamental to farm) interacts poorly with industry • Co-operation with industry is hampered by competition between companies • Co-operation with human health research should be improved European level • Strong support for European Centre for Epidemiology and Infectious Diseases • Co-operation with human health policy and research should be improved

  8. 2nd (final) meeting Agenda: discussion of priorities in draft Action Plan Major comments and recommendations: • More and sharper choices needed in research programming • Need for stronger interaction and co-operation between domains of animal and human health • Need for European Centre for Epidemiology and Infectious diseases is urgent; concern about continuity of budget if physical instead of virtual; task areas defined • Special attention required for activities contributing to a consistent European approach of regulatory issues

  9. Plan to continue (from 2008 on) Terms of reference: • Input in (inter)national research agendas from a shared opinion or mutual understanding of Dutch stakeholders; • Improvement of understanding and co-operation among stakeholders on the national level • Improvement of co-operation between human and animal health institutions Modus operandi: informal platform with participation of human health institutions working in the field of zoonoses (both food-borne and non food-borne)

  10. Direction of national research funding Under construction because of recent National Policy Agenda Animal Health. Longlist of topics: • Vaccine development for AI, AHS and RVF • BT-vaccination • Optimisation of vaccination strategies • Emerging zoonoses (also in companion animals) • Biology of vectors • Prevention and monitoring in non commercial animals • Differentiation of animal health policy • Elaboration of the OIE compartment concept • Improvement of early warning systems and tools • The concept of general disease resistance

  11. Thank you for your attention Time for questions

More Related